Last reviewed · How we verify
HU-014
HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor.
HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | HU-014 |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Drug class | Telomerase inhibitor |
| Target | Telomerase |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Telomerase is an enzyme that maintains telomeres, the protective caps on the ends of chromosomes. By inhibiting telomerase, HU-014 aims to induce apoptosis in cancer cells with high telomerase activity, thereby exerting its anti-tumor effects.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy (PHASE3)
- To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb (PHASE3)
- A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity (PHASE1)
- A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines (PHASE3)
- The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HU-014 CI brief — competitive landscape report
- HU-014 updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI